Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (Note: Request metadata listed "Tenax Therapeutics," but the filing text identifies the registrant as Synthetic Blood International, Inc.)
Reporting Period: Quarterly period ended October 31, 2003 (Six months ended October 31, 2003).
Status: Development stage company focused on perfluorocarbon-based blood substitutes (Oxycyte) and therapeutic oxygen carriers. The company has no commercial revenue and relies on financing to fund research and clinical trials.
Key Financial Metrics
| Metric | Three Months Ended Oct 31, 2003 | Six Months Ended Oct 31, 2003 | Oct 31, 2003 Balance Sheet |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(460,426) | $(912,336) | Accumulated Deficit: $(19,613,066) |
| EPS (Basic & Diluted) | $(0.005) | $(0.010) | N/A |
| Cash and Equivalents | N/A | N/A | $472,795 |
| Working Capital | N/A | N/A | $490,275 |
| Current Liabilities | N/A | N/A | $51,752 |
| Debt | N/A | N/A | Notes/Lease obligations included in financing activities; no long-term debt listed on balance sheet face. |
Cash Flow (Six Months Ended Oct 31, 2003):
- Net cash used in operating activities: $(805,561)
- Net cash used in investing activities: $(26,312)
- Net cash provided by financing activities: $1,126,226 (Primarily from private placement)
Material Changes vs. Prior Period
- Expense Reduction: Total expenses decreased significantly compared to the prior year. For the six months ended Oct 31, 2003, total expenses were $1,040,487 versus $1,458,909 in the prior year. This was driven by a reduction in Research and Development (R&D) costs (down from $1,013,547 to $498,710) due to the completion of late-stage animal studies in the prior year.
- Net Loss Improvement: Net loss for the six months decreased from $(1,427,370) in 2002 to $(912,336) in 2003.
- Financing Activity: The company raised $1,125,600 in the current period through a private placement of 7,320,000 shares, compared to minimal financing activity in the prior year.
- Cash Position: Cash and cash equivalents increased from $178,442 at April 30, 2003, to $472,795 at October 31, 2003.
Outlook, Risks, and Management Commentary
Operational Progress: The company received FDA approval for its Investigational New Drug (IND) application for Oxycyte. Phase I clinical trials began on October 30, 2003, with results from the first two dose levels consistent with expectations. The study is expected to conclude by the end of December 2003.
Liquidity and Capital Needs:
- Management believes current cash plus the anticipated completion of a $2,000,000 private placement will fund operations through approximately April 2004.
- As of the filing date, $1,125,600 had been raised in the private placement. A subsequent event noted an additional $296,000 raised in November 2003.
- The filing explicitly states that substantial additional financing will be required to continue clinical trials and that there is "substantial doubt" about the company's ability to continue as a going concern without such funding.
Risk Factors:
- Going Concern: The company has an accumulated deficit of nearly $20 million and expects to incur losses for the foreseeable future.
- Regulatory Risk: No assurance that clinical trials will meet endpoints or that FDA approval will be granted.
- Market Risk: High volatility in stock price and intense competition from companies with greater resources.
- Intellectual Property: Risks regarding patent enforcement and potential infringement claims.
Investor Verification Checklist
- Private Placement Completion: Verify if the full $2,000,000 private placement was successfully closed and if the registration statement for the restricted stock was filed.
- Clinical Trial Results: Confirm the final results of the Phase I Oxycyte safety study scheduled to end in December 2003.
- Going Concern Status: Assess the company's ability to secure additional funding beyond April 2004 to avoid curtailment of operations.
- Related Party Transactions: Review the $87,100 paid to a contract manufacturer where an officer is a minority shareholder/director.
- Auditor Changes: Note the resignation of corporate auditors in September 2003 and the appointment of successors in November 2003; verify the reasons for this change.